TITLE

MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation

AUTHOR(S)
Londoño, Maria-Carlota; Cárdenas, Andrés; Guevara, Mónica; Quintó, Llorenç; de las Heras, Dora; Navasa, Miguel; Rimola, Antoni; Garcia-Valdecasas, Juan-Carlos; Arroyo, Vicente; Ginès, Pere
PUB. DATE
September 2007
SOURCE
Gut;Sep2007, Vol. 56 Issue 9, p1283
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background/Aims: Serum sodium predicts prognosis in cirrhosis and may improve the prognostic accuracy of the model for end-stage liver disease (MELD) score, but the available information is limited. The aim of the present study was to assess the prognostic value of serum sodium in the prediction of survival at 3 and 12 months after listing in patients with cirrhosis awaiting liver transplantation, and to compare its predictive value with that of the MELD score. Patients and methods: 308 consecutive patients with cirrhosis listed for transplantation during a 5-year period were included in the study. The end-point was survival at 3 and 12 months before transplantation. Variables obtained at the time of listing were analysed for prognostic value using multivariable analysis. Accuracy of prognostic variables was analysed by receiver operating characteristic (ROC) curves. Results: The MELD score and serum sodium concentration were the only independent predictors of survival at 3 and 12 months after listing. Low serum sodium was associated with an increased risk of death in all subpopulations of patients with cirrhosis categorised according to the major complication developed before listing. The area under the ROC curves for serum sodium and MELD score was not significantly different both at 3 months (0.83 vs 0.79, respectively) and at 12 months (0.70 vs 0.77, respectively). The addition of serum sodium did not significantly improve the accuracy of the MELD score in the prediction of survival at 3 and 12 months. Conclusion: In patients with cirrhosis awaiting liver transplantation, serum sodium and MELD were found to be independent predictors of survival. Larger studies are needed to determine whether the addition of serum sodium to MELD can improve its prognostic accuracy.
ACCESSION #
26437241

 

Related Articles

  • Alcoholics and Liver Transplantation. Cohen, Carl; Benjamin, Martin // JAMA: Journal of the American Medical Association;3/13/91, Vol. 265 Issue 10, p1299 

    Presents arguments underlying a widespread unwillingness to consider patients with alcoholic cirrhosis of the liver as candidates for transplantation. Reasons for precluding alcoholics as candidates for liver transplantation; Moral and medical argument on the issue; Selection process of liver...

  • A 50-Year-Old Man With Hepatitis C and Cirrhosis Needing Liver Transplantation, 18 Months Later. Ship, Amy N. // JAMA: Journal of the American Medical Association;4/27/2005, Vol. 293 Issue 16, p2027 

    Presents an update to the case of a 50-year-old man with hepatitis C and cirrhosis needing a liver transplant. Details of his case and medical condition; Previous medical history; Comments of the patient on his condition after having a living related donor transplantation; Way that he is...

  • Nutritional assessment in liver cirrhosis. Moriwaki, Hisataka // Journal of Gastroenterology;May2006, Vol. 41 Issue 5, p511 

    The article reflects the author's view on the nutritional assessment in liver cirrhosis. He agreed that the prevalence of protein-energy malnutrition in patients with liver cirrhosis is high. Thus, it is an important factor in analyzing their survival rate, length of hospital stay, prognosis...

  • Sepsis and Solid Organ Transplantation. Kalil, A. C.; Dakroub, H.; Freifeld, A. G. // Current Drug Targets;Apr2007, Vol. 8 Issue 4, p533 

    Approximately seventy patients undergo solid organ transplantation (SOT) every day in the United States. Sepsis remains the first or second most common cause of death in transplant recipients, depending on the allograft type. The rapid diagnosis and treatment of sepsis is critical to ensure...

  • Bile bilirubin pigment analysis in disorders of bilirubin metabolism in early infancy. Lee, W. S.; McKiernan, P. J.; Beath, S. V.; Preece, M. A.; Baty, D.; Kelly, D. A.; Burchell, B.; Clarke, D. J. // Archives of Disease in Childhood;Jul2001, Vol. 85 Issue 1, p38 

    Background-Early and accurate diagnosis of Crigler-Najjar syndrome, which causes prolonged unconjugated hyperbilirubinaemia in infancy, is important, as orthotopic liver transplantation is the definitive treatment. Aim-To determine whether biirubin pigment analysis of bile in infants with...

  • To TOE or not to TOE? That is the question in patients with portal hypertension and varices. Leung, Christopher; Sern Wei Yeoh; Lim, Lucy Y.; Boyapati, Ray; Testro, Adam G.; Vaughan, Rhys; Marion, Kaye; Burrell, Louise M.; Angus, Peter W. // Gut;Apr2013, Vol. 62 Issue 4, p655 

    A letter to the editor is presented in response to the article "Management of patients with cirrhosis awaiting liver transplantation" by A Cardenas and P. Gines in the 2011 issue.

  • Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. Bird, George I.A.; O'Grady, John G.; Harvey, Felicity A.H.; Calne, Roy Y.; Williams, Roger // BMJ: British Medical Journal (International Edition);7/1/90, Vol. 301 Issue 6742, p15 

    Evaluates the outcome of liver transplantation in patients with alcoholic cirrhosis in England. Percentage of the survival rate of patients in one year; Criteria for the selection of liver transplantation in patients; Indication of the return to drinking by patients.

  • FDA grants orphan drug designation for Novel Terlipressin Formulation for treatment of ascites.  // Transplant News;Jan2013, Vol. 23 Issue 1, p10 

    The article reports that Thoratec Corporation, Pleasanton, California, has been granted an Investigational Device Exemption (IDE) by the FDA to start the Randomized Evaluation of VAD InterVention before Inotropic Therapy (REVIVE-IT) study, using the HeartMate II, a Ventricular Assist System.

  • Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Zwaveling, J; Bredius, R G M; Cremers, S C L M; Ball, L M; Lankester, A C; Teepe-Twiss, I M; Egeler, R M; den Hartigh, J; Vossen, J M // Bone Marrow Transplantation;Jan2005, Vol. 35 Issue 1, p17 

    Summary:We studied the pharmacokinetics of intravenous busulfan (Bu) in children in order to further optimize intravenous Bu dosing in relation to toxicity and survival. A total of 31 children undergoing Bu-based conditioning for allogeneic SCT were enrolled in a study. The starting dose was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics